title: Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa.
authors.forename: P
authors.initials: P
authors.lastname: Arriola-Villalobos
authors.forename: D
authors.initials: D
authors.lastname: Díaz-Valle
authors.forename: N
authors.initials: N
authors.lastname: Alejandre-Alba
authors.forename: C
authors.initials: C
authors.lastname: López-Abad
authors.forename: R
authors.initials: R
authors.lastname: Méndez-Fernández
authors.forename: J M
authors.initials: JM
authors.lastname: Benítez-del-Castillo
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D002177:Candidiasis / Q000139:chemically induced*; D002825:Chorioretinitis / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept